This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
BSXNegative Net Change WSTPositive Net Change INGNPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
by Zacks Equity Research
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
BSXNegative Net Change WSTPositive Net Change PACBNo Net Change MEDPNegative Net Change
earnings medical medical-devices
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
BSXNegative Net Change WSTPositive Net Change DOCSNegative Net Change GEHCNegative Net Change
earnings medical medical-devices
AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.
BSXNegative Net Change AMNPositive Net Change WSTPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HALONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reddit Inc. (RDDT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RDDTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
by Zacks Equity Research
SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.
BSXNegative Net Change WSTPositive Net Change MEDPNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
BDXPositive Net Change CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
BSXNegative Net Change MEDPNegative Net Change WGSNegative Net Change TEMPositive Net Change
earnings medical medical-devices
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
by Moumi Mondal
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
ABTPositive Net Change DHRPositive Net Change HOLXNegative Net Change
medical medical-devices
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
by Urmimala Biswas
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
UNHNegative Net Change CVSPositive Net Change HLFNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-surprise healthcare medical medical-devices
XRAY Stock Rises on Q2 Earnings & Revenues Beat, Adjusted Margins Up
by Zacks Equity Research
DENTSPLY SIRONA tops Q2 earnings estimates with margin gains, but revenue declines and U.S. weakness persists.
BSXNegative Net Change XRAYPositive Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
by Zacks Equity Research
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
BSXNegative Net Change BDXPositive Net Change WSTPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
by Debanjana Dey
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
MEDNegative Net Change HIMSNegative Net Change TEMPositive Net Change
medical medical-devices
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RIGLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WGSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Piper Sandler Companies (PIPR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PIPRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CB Financial Services (CBFV) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CBFVPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View
by Zacks Equity Research
McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.
BSXNegative Net Change MCKNegative Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
ACB Stock Down as Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Aurora Cannabis stock slips after Q1 earnings miss, but revenue climbs 17.5% year over year on strong global medical cannabis demand.
BSXNegative Net Change WSTPositive Net Change MEDPNegative Net Change ACBNegative Net Change
earnings medical medical-devices
Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
AVNS shares dip 12% as Q2 earnings miss estimates, margins shrink, and tariff pressures weigh on profitability.
BSXNegative Net Change WSTPositive Net Change MEDPNegative Net Change AVNSNegative Net Change
earnings medical medical-devices
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand
by Zacks Equity Research
QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.
BSXNegative Net Change QDELPositive Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
BSXNegative Net Change DVANegative Net Change WSTPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
BSXNegative Net Change MASINegative Net Change WSTPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
by Zacks Equity Research
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
BSXNegative Net Change FMSPositive Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices